Fig. 1 · Structure

Documents & Downloads

IPI-493

Cat. No. A11272 CAS 64202-81-9

HSP90 inhibitor

IPI-493 is a potent and orally bioavailable HSP90 inhibitor with Ki of 21 nM.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vitro Studies

In the DMBC22 cell line, treatment with the tested compound at 0.4 μM in culture medium for 72 h markedly reduced viability by 52%, as evidenced by changes in acid phosphatase activity. DMBC11 cells were exposed to 0.4 μM 17-aminogeldanamycin (AG) for 22 h. CCND1 mRNA level was further reduced to about 50% of control. In fixed ACE2 cerulean cells, the tested compound was incubated with S1-OFP before treatment of the cells. Inhibition of fluorescent spike protein binding to hACE2 cerulean was observed compared with DMSO control. In DMBC21 cells, treatment with the study compound at 0.4 μM in culture medium for 72 h further increased the percentages of cells with active caspase-3/7 up to 30–35% and was associated with cell detachment, compared with GEL at the same concentration. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced Viability in the DMBC22 Cell Line

Cell-based study · DMBC22 cell line [1]

In the DMBC22 cell line, treatment with the tested compound at 0.4 μM in culture medium for 72 h markedly reduced viability by 52%, as evidenced by changes in acid phosphatase activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
viability in DMBC22 cell lineviable cell number 52%[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.4 μM
Exposure duration
72 h
Method
drugs were dissolved in the culture medium
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: IPI-493; Compound label in the paper: 17-Aminogeldanamycin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Drugs (S12, S13); Results > AG is also effective against NRASQ61R melanoma cells (S95, S96, S106)

viability in DMBC22 cell line: viability in DMBC22 cell line; comparator: control — Results > AG is also effective against NRASQ61R melanoma cells (S96)

Reduced CCND1 mRNA in DMBC11 Cells

Cell-based study · DMBC11 [2]

DMBC11 cells were exposed to 0.4 μM 17-aminogeldanamycin (AG) for 22 h. CCND1 mRNA level was further reduced to about 50% of control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCND1 mRNA levelCCND1 mRNA level about 50% of control[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.4 μM
Exposure duration
22 h
Method
exposed to 0.4 μM 17-aminogeldanamycin (AG)
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: IPI-493; Compound label in the paper: 17-Aminogeldanamycin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.4. AG Diversely Affects Transcript and Proteins Levels of Different NF-κB-Dependent Genes (S35, S36, S37); 4. Materials and Methods > 4.1. Cell Culture (S51, S54); Figure 4 legend (S145)

CCND1 mRNA level: CCND1 mRNA level; comparator: control — 2. Results > 2.4. AG Diversely Affects Transcript and Proteins Levels of Different NF-κB-Dependent Genes (S37)

Fluorescent spike protein binding inhibition in fixed cells

Cell-based study · fixed ACE2 cerulean cells [3]

In fixed ACE2 cerulean cells, the tested compound was incubated with S1-OFP before treatment of the cells. Inhibition of fluorescent spike protein binding to hACE2 cerulean was observed compared with DMSO control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
binding of fluorescent spike protein to hACE2 ceruleanReported result inhibition of S1 protein binding with ACE2 was observed in 17-Aminodemethoxygeldanamycin[3]

Literature-Reported Treatment Conditions

Exposure duration
for 15 min
Method
incubated with S1-OFP for 1 h and further treated with fixed ACE2 cerulean cells
Vehicle
DMSO
Co-treatment
Other interventions in this design: S1-OFP. Compound effect isolated by the comparison: when compared with DMSO control.
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: IPI-493; Compound label in the paper: 17-Aminodemethoxygeldanamycin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > ACE2– spike S1- binding study (S71, S73); Results > ACE2-S1-binding assay (S136, S137, S138)

binding of fluorescent spike protein to hACE2 cerulean: binding of fluorescent spike protein to hACE2 cerulean; comparator: DMSO control — Results > ACE2-S1-binding assay (S136, S138)

Increased active caspase percentages and cell detachment

Cell-based study · DMBC21 [1]

In DMBC21 cells, treatment with the study compound at 0.4 μM in culture medium for 72 h further increased the percentages of cells with active caspase-3/7 up to 30–35% and was associated with cell detachment, compared with GEL at the same concentration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Percentages of cells with active caspase-3/7cells with active caspase-3/7 30–35%[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.4 μM
Exposure duration
72 h
Method
drugs were dissolved in the culture medium
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: IPI-493; Compound label in the paper: 17-Aminogeldanamycin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Drugs (S12, S13); Materials and methods > A time-lapse fluorescent microscopy (S18); Results > 17-Aminogeldanamycin (AG) is more effective than geldanamycin (GEL) in caspase-3/7 activation in melanoma cells (S44, S45, S46); Fig. 1 legend (S112)

Percentages of cells with active caspase-3/7: Percentages of cells with active caspase-3/7; comparator: GEL at this concentration — Results > 17-Aminogeldanamycin (AG) is more effective than geldanamycin (GEL) in caspase-3/7 activation in melanoma cells (S46); Fig. 1 legend (S112)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 64202-81-9
Applications HSP90 inhibitor
Formula C28H39N3O8
Molecular Weight 545.62
Synonyms NSC 255109; 17-Aminogeldanamycin; 17-Aminodemethoxygeldanamycin; 17-Amino-17-demethoxygeldanamycin
SMILES
CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(N)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Mielczarek-Lewandowska A, Sztiller-Sikorska M, Osrodek M, et al. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes. Apoptosis (2019). PMID: 30989459 DOI: 10.1007/s10495-019-01542-y Source material
  2. [2] Hartman ML, Rogut M, Mielczarek-Lewandowska A, et al. 17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines. Int J Mol Sci (2020). PMID: 32466509 DOI: 10.3390/ijms21113749 Source material
  3. [3] Jancy SV, Lupitha SS, Chandrasekharan A, et al. A high-throughput screening system for SARS-CoV-2 entry inhibition, syncytia formation and cell toxicity. Biol Proced Online (2023). PMID: 37495994 DOI: 10.1186/s12575-023-00214-1 Source material

Added to your cart

View Cart Checkout
Loading...